Risk Factors Predictive of Para-Aortic Lymph Node Metastasis in Endometrial Carcinomas*

Abstract Background A nomogram was developed to predict lymph node metastasis (LNM) for patients with early-stage esophageal squamous cell carcinoma (ESCC). Methods We used the clinical data of ESCC patients with pathological T1 stage disease who underwent surgery from January 2011 to June 2018 to develop a nomogram model. Multivariable logistic regression was used to confirm the risk factors for variable selection. The risk of LNM was stratified based on the nomogram model. The nomogram was validated by an independent cohort which included early ESCC patients underwent esophagectomy between July 2018 and December 2019. Results Of the 223 patients, 36 (16.1%) patients had LNM. The following three variables were confirmed as LNM risk factors and were included in the nomogram model: tumor differentiation (odds ratio [OR] = 3.776, 95% confidence interval [CI] 1.515–9.360, p = 0.004), depth of tumor invasion (OR = 3.124, 95% CI 1.146–8.511, p = 0.026), and tumor size (OR = 2.420, 95% CI 1.070–5.473, p = 0.034). The C-index was 0.810 (95% CI 0.742–0.895) in the derivation cohort (223 patients) and 0.830 (95% CI 0.763–0.902) in the validation cohort (80 patients). Conclusions A validated nomogram can predict the risk of LNM via risk stratification. It could be used to assist in the decision-making process to determine which patients should undergo esophagectomy and for which patients with a low risk of LNM, curative endoscopic resection would be sufficient.

Download Full-text

A retrospective study of the risk factors and the prognosis in patients with papillary thyroid carcinoma depending on the number of lymph node metastasis

Clinical and Experimental Medicine ◽

10.1007/s10238-020-00675-8 ◽

2021 ◽

Author(s):

Zhong Ying Rui ◽

Yang Liu ◽

Wei Zheng ◽

Xuan Wang ◽

Zhao Wei Meng ◽

...

Keyword(s):

Risk Factors ◽

Lymph Node ◽

Retrospective Study ◽

Papillary Thyroid Carcinoma ◽

Lymph Node Metastasis ◽

Thyroid Carcinoma ◽

Papillary Thyroid ◽

Node Metastasis

Download Full-text

Pembrolizumab-Induced Severe Neuropathy in a Patient with Metastatic Urothelial Carcinoma after Achieving Complete Response: Guillain-Barré Syndrome-Like Onset

Case Reports in Oncology ◽

10.1159/000511567 ◽

2020 ◽

Vol 13 (3) ◽

pp. 1490-1494

Author(s):

Shuntaro Aoki ◽

Masato Yasui ◽

Hironao Tajirika ◽

Hideyuki Terao ◽

Makoto Funahashi ◽

...

Keyword(s):

Lymph Node ◽

Lymph Node Metastasis ◽

Urothelial Carcinoma ◽

Lung Metastases ◽

Complete Response ◽

Guillain Barre Syndrome ◽

Node Metastasis ◽

Aortic Lymph Node ◽

Guillain Barré Syndrome ◽

Guillain Barré

An 85-year-old female was admitted to our hospital for left ureteral cancer and para-aortic lymph node metastasis. To control hematuria, a laparoscopic retroperitoneal nephroureterectomy was performed, and papillary urothelial carcinoma (pT3b) was found. To treat para-aortic lymph node metastasis, she received chemotherapy with gemcitabine and nedaplatin. After 2 cycles, a computed tomography scan revealed its disappearance; however, bilateral lung metastases appeared. The patient was administered second-line therapy with pembrolizumab every 3 weeks. After 3 courses, lung metastases disappeared and she achieved a complete response. After the fifth administration of pembrolizumab, she was readmitted with right upper limb pain and weakness in both lower extremities. She was diagnosed with pembrolizumab-induced grade 3 peripheral neuropathy with Guillain-Barré syndrome-like onset. High-dose monocorticotherapy was initiated for treatment. Three weeks later, the pain and weakness of the limbs improved. After discharge, the dose of prednisolone was tapered and there was no relapse of adverse events. Pembrolizumab was discontinued at the onset of neuropathy, but she maintained a complete response.

Download Full-text